BRPI0713342A2 - Composições e kits compreendendo um componente de melatonina e um componente de ácido graxo ômega -3 - Google Patents

Composições e kits compreendendo um componente de melatonina e um componente de ácido graxo ômega -3 Download PDF

Info

Publication number
BRPI0713342A2
BRPI0713342A2 BRPI0713342-1A BRPI0713342A BRPI0713342A2 BR PI0713342 A2 BRPI0713342 A2 BR PI0713342A2 BR PI0713342 A BRPI0713342 A BR PI0713342A BR PI0713342 A2 BRPI0713342 A2 BR PI0713342A2
Authority
BR
Brazil
Prior art keywords
component
kits
compositions
fatty acid
melatonin
Prior art date
Application number
BRPI0713342-1A
Other languages
English (en)
Inventor
Velazquez Jesus
Violet Trejo Amy
Patrick Ebel James
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of BRPI0713342A2 publication Critical patent/BRPI0713342A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

COMPOSIÇÕES e KITS COMPREENDENDO UM COMPONENTE DE MELATONINA E UM COMPONENTE DE ÁCIDO GRAXO âMEGA-3. A presente invenção refere-se a composições e kits, sendo que cada composição compreende um componente de melatonina, um componente de ácido graxo ômega-3, ou ambos, e sendo que cada kit compreende um componente de melatonina e um componente de ácido graxo ômega-3. As composições e os kits são úteis para a restauração da função do sono e para benefícios à pele. Também são apresentados na presente invenção os métodos para uso das composições e kits.
BRPI0713342-1A 2006-06-23 2007-06-22 Composições e kits compreendendo um componente de melatonina e um componente de ácido graxo ômega -3 BRPI0713342A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81598806P 2006-06-23 2006-06-23
US60/815,988 2006-06-23
PCT/IB2007/052438 WO2007148308A2 (en) 2006-06-23 2007-06-22 Compositions and kits comprising a melatonin component and an omega-3-fatty acid component

Publications (1)

Publication Number Publication Date
BRPI0713342A2 true BRPI0713342A2 (pt) 2012-03-06

Family

ID=38740977

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713342-1A BRPI0713342A2 (pt) 2006-06-23 2007-06-22 Composições e kits compreendendo um componente de melatonina e um componente de ácido graxo ômega -3

Country Status (9)

Country Link
US (1) US20070299127A1 (pt)
EP (1) EP2032133A2 (pt)
JP (1) JP2009539968A (pt)
CN (1) CN101460160A (pt)
AU (1) AU2007262360A1 (pt)
BR (1) BRPI0713342A2 (pt)
CA (1) CA2654459A1 (pt)
MX (1) MX2008016271A (pt)
WO (1) WO2007148308A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2900331B1 (en) * 2012-09-26 2021-09-01 Feuerstein, Seth, D. Combination methods and compositions including sleep therapeutics for treating mood
JP6650852B2 (ja) * 2016-09-14 2020-02-19 マルハニチロ株式会社 ドコサヘキサエン酸を含有する睡眠の質改善剤
WO2020117997A1 (en) * 2018-12-05 2020-06-11 The Procter & Gamble Company Container for personal health compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591768A (en) * 1990-12-04 1997-01-07 State Of Oregan, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Methods for treating circadian rhythm phase disturbances
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US6344482B1 (en) * 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
EP0951842B1 (en) * 1999-01-20 2002-12-04 N.V. Nutricia Infant formula
US20030224071A1 (en) * 1999-08-20 2003-12-04 Howard Murad Pharmaceutical compositions and methods for managing connective tissue ailments
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
GB0128674D0 (en) * 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
ITMI20030036A1 (it) * 2003-01-13 2004-07-14 Hunza Di Pistolesi Elvira & C S A S Preparazioni farmacologiche o dietetiche costituite da
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US20070086972A1 (en) * 2005-09-12 2007-04-19 Jacob Birnbaum Hair growth compositions and methods for treating hair loss or related conditions

Also Published As

Publication number Publication date
MX2008016271A (es) 2009-03-09
CA2654459A1 (en) 2007-12-27
AU2007262360A1 (en) 2007-12-27
US20070299127A1 (en) 2007-12-27
WO2007148308A2 (en) 2007-12-27
JP2009539968A (ja) 2009-11-19
WO2007148308A3 (en) 2008-10-23
EP2032133A2 (en) 2009-03-11
CN101460160A (zh) 2009-06-17

Similar Documents

Publication Publication Date Title
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
BRPI0510716A (pt) uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
BRPI0507031A (pt) composições nematocidas e métodos de uso dessas
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
BRPI0617294B8 (pt) composição farmacêutica em gel hidroalcóolico e uso de testosterona
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
ECSP088884A (es) Compuestos heterociclicos fusionados y su uso como moduladores de mglur5
CR10149A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
CR11731A (es) Composiciones y procedimientos para su preparación y uso
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
GT200600194A (es) Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada
BRPI0721137B8 (pt) compostos para modulação de atividade de c-fms e/ou kit, composição, kit e uso dos referidos compostos.
BRPI0609765A8 (pt) mistura de isoalcano, método para a preparação da mesma, composição cosmética ou farmacêutica, e, uso de uma mistura de isoalcano
ECSP099296A (es) Inmuno-reguladores, preparaciones y composiciones que incluyen los inmuno-reguladores, pruebas para evaluar la actividad de los inmuno-reguladores y preparaciones y composiciones que incluyen los mismos y métodos
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
BRPI0702163A (pt) composições de toner e métodos
CL2007002970A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
AR059851A1 (es) Anticuerpos de la egfl7 y metodos de uso

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 5A ANUIDADE.